Pharmaceutical intermediates
Cenobamate Intermediates
3 pharmaceutical intermediates for Cenobamate. Indication: Partial seizures; epileptic seizures; epilepsy.
About Cenobamate
- Originator
- SK Biopharmaceuticals Co Ltd
- Indication
- Partial seizures; epileptic seizures; epilepsy
- Approved Date
- 03/10/2020
- NCE Patent
- 03/10/2025
- DS/DP
- 10/30/2032
Available intermediates
3 intermediates currently listed for Cenobamate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 2-Bromo-2'-chloroacetophenone | 5000-66-8 | / | / |
| 1-(2-chlorophenyl)-2-(1,2,3,4-tetrazol-2-yl)ethan-1-one | 1259059-71-6 | / | / |
| Cenobamate N-1 intermediate | 1259059-77-2 | / | / |
Building toward Cenobamate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →